KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Operating Leases (2019 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Operating Leases for 7 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 16.14% to $6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Dec 2025, down 16.14% year-over-year, with the annual reading at $6.4 million for FY2025, 16.14% down from the prior year.
  • Operating Leases for Q4 2025 was $6.4 million at Xenon Pharmaceuticals, down from $6.8 million in the prior quarter.
  • The five-year high for Operating Leases was $10.4 million in Q1 2023, with the low at $2.6 million in Q3 2021.
  • Average Operating Leases over 5 years is $7.5 million, with a median of $7.8 million recorded in 2021.
  • The sharpest move saw Operating Leases surged 1260.64% in 2021, then dropped 20.39% in 2024.
  • Over 5 years, Operating Leases stood at $7.7 million in 2021, then rose by 29.99% to $9.9 million in 2022, then dropped by 3.45% to $9.6 million in 2023, then decreased by 20.39% to $7.6 million in 2024, then dropped by 16.14% to $6.4 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $6.4 million, $6.8 million, and $7.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.